Top 10 Biotech Stocks To Buy For 2019

Alexion Pharmaceuticals (ALXN) jumped to the top of the S&P 500 today after Barclays upgraded the biotech stock to Overweight from Equal Weight citing fewer macro headwinds.

Getty Images

Shares of Alexion Pharmaceuticals gained 5.2% to $125.59, while the S&P 500 rose 0.1%.

Barclays analyst Geoff Meacham and team explain why they upgraded Alexion Pharmaceuticals:

We are upgrading shares ofAlexion to Overweight and increasing our PT to $155 from $150 on an improved outlook for 2017. Specifically, we see lower FX and fewer macroeconomic risks to the core base business over the next 12 months. We also expect approval of Soliris in refractory gMG by YE17 following a planned regulatory submission in 1Q17, which could add another growth lever in early 2018 at the latest. Our upgrade is not a call on the recent 10-Q delay, which according to our discussions with management has to do with an investigation into sales practices following allegations by a former employee. We also do not anticipate major restatements of historical Soliris sales due to the investigation. Furthermore, this is not a call on Kanuma or the Synageva deal, as we have cut our Kanuma sales in our P&L and reduced its contribution in our NPV valuation. Indeed, we would expect minimal weakness inAlexion shares if the company were to take a write-down on Synageva during 2017, but this is not core to our investment thesis. In sum, our bullishness onAlexion shares is due to: 1) lessened FX and macroeconomic headwinds in 2017, 2) near-term Soliris growth from likely regulatory approval in refractory gMG, and 3) attractive upside potential from current levels as the pipeline including line extensions for Soliris and new assets such as 1210 mature.

Top 10 Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiranappears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.

Top 10 Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Private Capital Group LLC boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 1,703.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,362 shares of the medical research company’s stock after purchasing an additional 2,231 shares during the period. Private Capital Group LLC’s holdings in Amgen were worth $403,000 at the end of the most recent reporting period.

  • [By Cory Renauer]

    Patient Amgen Inc.(NASDAQ:AMGN) shareholders have seen the stock quadruple in price over the past decade, plus they’ve enjoyed one of the fastest-growing dividends in biopharma. Now that the company’s launched a new migraine headache drug, investors are wondering if the former highflier can put on another memorable performance.

  • [By Shane Hupp]

    Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $63.15 million flowed into the stock on the tick-up and $134.51 million flowed out of the stock on the tick-down, for a money net flow of $71.36 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $2.11 for the day and closed at $185.79

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is expected to release its most recent quarterly results on Thursday. The consensus forecast calls for $3.54 in EPS and $5.74 billion in revenue for the second quarter. Shares traded on Fridays close at $190.60. The consensus price target is $196.10, and the 52-week range is $163.31 to $201.23.

Top 10 Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Woodford Investment Management LLP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP

    These are the top 5 holdings of Woodford Investment Management LLPProthena Corp PLC (PRTA) – 11,557,614 shares, 37.95% of the total portfolio. Shares added by 0.25%Alkermes PLC (ALKS) – 5,270,428 shares, 27.32% of the total portfolio. Shares reduced by 30.52%Theravance Biopharma Inc (TBPH) – 10,898,879 shares, 23.64% of the total portfolio. Shares added by 1.41%Biogen Inc (BIIB) – 279,564 shares, 6.85% of the total portfolio. Shares reduced by 24.56%Evofem Biosciences Inc (EVFM) – 7,465,538

  • [By Cory Renauer]

    There’s a lot for investors to like aboutAmgen Inc. (NASDAQ:AMGN) andBiogen Inc. (NASDAQ:BIIB). Both of these biotech stocks have produced tremendous returns over the past couple of decades, and the businesses they represent still generate enormous profits.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage gain ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded up about 19% at $355.17. The stocks 52-week range is $249.17 to $370.57. Volume was over 12 million compared to the daily average volume of 1.6 million.

  • [By Todd Campbell]

    Drugmakers’ dustbins are filled with failed attempts to slow the progression of Alzheimer’s disease, yet drug developers, includingBiogen(NASDAQ:BIIB), remain undaunted in their pursuit of new treatments. Recently, Biogen reported data from a midstage trial that suggests it could be rewarded for its perseverance. In hundreds of patients, the company’s BAN2401 successfully slowed disease progression as measured by the Alzheimer’s Disease Composite Score (ADCOMS). Is this the breakthrough patients have been waiting for?

Top 10 Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

Actively managed blockchain ETF joins suddenly crowded field

A new blockchain exchange-traded fund launched Wednesday on the New York Stock Exchange.

The REX BKCM ETF (BKC) holds shares of 32 companies working in cryptocurrencies or their underlying blockchain technology. The ETF is run by Rex Shares and actively managed by Brian Kelly, a CNBC contributor and head of BKCM, which runs a digital assets strategy for clients.

BKC traded little changed Wednesday morning near $25.14 a share. As of launch, the ETF’s five largest holdings were: Taiwan Semiconductor Manufacturing, Global Unichip, GMO Internet, Overstock.com and SVB Financial Group. Each had an 8 percent weighting in the ETF.

show chapters

Bitcoin, digital currencies and block chain are one of the biggest opportunities of our generation: Brian Kelly    6 Mins Ago | 03:34

The fund also holds shares of Square and chipmaker Advanced Micro Devices. It has an expense ratio of 0.88 percent.

“I get asked all the time on how to invest in blockchain technology without dealing with storage, the fears of hacking, hedge funds, etc. My hope is the BKC ETF can provide this desired equity allocation to institutions and individuals alike,” Kelly said in a statement.

Bitcoin is the first application of blockchain technology, which quickly creates a permanent record of transactions between two parties and eliminates the need for a third party, such as a bank. Prices of bitcoin and other cryptocurrencies have skyrocketed in the last 18 months on increased investor interest. However, the Securities and Exchange Commission has not yet allowed a bitcoin ETF to list due to issues such as liquidity and extreme price volatility.

Four other blockchain ETFs launched in the U.S. in January: First Trust Indxx Innovative Transaction & Process ETF (LEGR), Reality Shares Nasdaq NexGen Economy ETF (BLCN), Amplify Transformational Data Sharing ETF (BLOK) and Innovation Shares NextGen Protocol ETF (KOIN).

All four funds fell single digits from the end of January to the end of March, but are up slightly for the second quarter so far.

Best Safest Stocks For 2019

Things aren’t going to script right now in the financial sector. It’s a widely established fact (based on years of historical evidence) that banks and other lenders typically prosper when interest rates are rising. In previous rate-tightening cycles, the financial sector was usually among the market’s top performers.

—Recommended Link— Create A 10%+ Income Stream For Life
We’re sitting on a collection of the safest, most generous monthly payers available. And while $11,200 in dividend checks is a welcome addition to anyone’s income, investors also love racking up capital gains as high as 446%. Start generating a 10%+ income stream for life today from these consistent companies.

As I’ve discussed before in my High-Yield Investing premium newsletter, banks can feast in these conditions because the rates they charge borrowers on loans usually rise faster than the rates they pay to depositors. That widens net interest margins (NIMs) and fattens the bottom line.

Best Safest Stocks For 2019: NIC Inc.(EGOV)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of NIC (NASDAQ:EGOV) from a buy rating to a strong-buy rating in a research note published on Friday morning.

    Several other research firms also recently commented on EGOV. Zacks Investment Research downgraded NIC from a hold rating to a sell rating in a report on Monday, January 8th. ValuEngine downgraded NIC from a sell rating to a strong sell rating in a report on Wednesday, May 2nd. Barrington Research restated a hold rating on shares of NIC in a report on Monday, April 30th. TheStreet downgraded NIC from a b- rating to a c rating in a report on Thursday, March 8th. Finally, Loop Capital decreased their price objective on NIC to $14.00 and set a hold rating for the company in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $18.33.

  • [By Max Byerly]

    Shares of NIC Inc. (NASDAQ:EGOV) have earned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $18.00.

  • [By Joseph Griffin]

    Media headlines about NIC (NASDAQ:EGOV) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NIC earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the software maker an impact score of 44.2220263592641 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Joseph Griffin]

    NIC Inc. (NASDAQ:EGOV) has been given a consensus recommendation of “Hold” by the ten research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $18.00.

Best Safest Stocks For 2019: Western Asset Mortgage Capital Corporation(WMC)

Advisors’ Opinion:

  • [By Max Byerly]

    ValuEngine lowered shares of Western Asset Mortgage Capit (NYSE:WMC) from a buy rating to a hold rating in a research report report published on Wednesday.

Best Safest Stocks For 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed most recently at $36.18, with a consensus price target of $57.38 and a 52-week range of $15.97 to $40.65.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

  • [By ]

    In the Lightning Round, Cramer was bullish on Ingersoll-Rand (IR) , The Blackstone Group (BX) , Thermo Fisher Scientific (TMO) , FMC Corp (FMC) , Nike (NKE) , Zebra Technologies (ZBRA) and Aimmune Therapeutics (AIMT) .

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Shane Hupp]

    Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Wednesday. They currently have a $72.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 117.59% from the company’s previous close.

Best Safest Stocks For 2019: Infinity Pharmaceuticals, Inc.(INFI)

Advisors’ Opinion:

  • [By Logan Wallace]

    ValuEngine upgraded shares of Infinity Pharmaceuticals (NASDAQ:INFI) from a sell rating to a hold rating in a report published on Saturday morning.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares made a healthy gain early on Tuesday after the firm announced a collaboration with Arcus Biosciences Inc. (NYSE: RCUS). These two companies have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types that typically show minimal response to checkpoint inhibition monotherapy.

Best Safest Stocks For 2019: Royal Dutch Shell PLC(RDS.A)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Royal Dutch Shell plc ADR Class A (RDS.A)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Royal Dutch Shell plc ADR Class A (RDS.A)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Alexander Bird]

    Much of Wall Street will tell you to stick with the oil industry giants – companies like Exxon Mobil Corp. (NYSE: XOM) or Royal Dutch Shell Plc. (NYSE: RDS.A).

What Happened in the Stock Market Today

Stocks opened lower Thursday but drifted higher during the session. TheDow Jones Industrial Average (DJINDICES:^DJI)finished a small loss and theS&P 500 (SNPINDEX:^GSPC)closed higher.

Today’s stock market

Index Percentage Change Point Change
Dow (0.03%) (7.66)
S&P 500 0.49% 13.86

Data source: Yahoo! Finance.

Technology stocks led the market, with Applemaking history by being the first U.S. company to break through $1 trillion in market capitalization. TheTechnology Select Sector SPDR ETF (NYSEMKT:XLK) gained 1.3%. The materials sector lagged; theiShares US Basic Materials ETF (NYSEMKT:IYM) fell 1%.

As for individual stocks, Sonos (UNKNOWN:UNKNOWN) rose on its first day of public trading, and Blue Apron (NYSE:APRN) tumbled following a disappointing quarterly report.

Absrtact stock graphs and prices.

Image source: Getty Images.

Sonos soars in trading debut

Sonos, maker of high-end speakers for the home audio market, traded publicly for the first time today, and shares soared 32.7% above the initial public offering price of $15. Sonos had lowered the offering price below the $17-$19 target range that was given in the registration statementit filed last week.

Sonos offered 5.6 million shares and current shareholders offered 8.3 million shares in the offering. Options on another 2.1 million shares are available to the underwriters from the company and existing shareholders. After the offering, there are a total of 98.4 million shares outstanding, giving the company a market capitalization of $2 billion. About 86% of the shares outstanding are held by current shareholders under a lock-up period for 180 days.Options for about 50 million additional shares have been issued by the company as part of its incentive plan.

The company has had success selling wireless, multiroom speaker systems known for their audio quality, and has expanded into home theater and voice-activated speakers. Revenue in 2017 was $992.5 million, a 10.1% increase from the year before, but sales appear to be accelerating, with revenue in the first two quarters of the 2018 fiscal year up 18% over the first half last year. The company is not yet profitable, with a loss of $0.25 per share last year, an improvement on a $0.71-per-share loss in 2016.

Sonos is facing some stiff competition in the speaker market from players with deep pockets, such as Apple, Amazon, and Alphabet, as well as from new entrants like Roku. Investors were ready to buy into the company’s risky proposition today, though.

Blue Apron tumbles as customer numbers shrink

Shares of meal-kit company Blue Apron got hammered today, plummeting 24.4% after the company failed to meet already-low sales expectations for the second quarter and reported that it’s losing customers at a rapid pace. Net revenue fell 25% to $180 million, compared with analyst expectations for a 21% decline. Net loss per share was $0.17, $0.01 less than the analyst consensus. The number of customers decreased 24% from the period a year earlier, and fell 9% from last quarter.

There was a little good news in the quarter, with the average orders per customer holding steady from last quarter at 4.4, and the average order value ticking up from $56.58 in Q1 to $57.34 in Q2. The cost of goods sold improved to 64.7% compared with 68.7% in Q2 last year and 65.8% in Q1 as the company made efficiency improvements. But Blue Apron had reported a sequential increase in customers last quarter, expressing optimism that momentum would continue, and that didn’t happen, with the company clearly having trouble attracting new subscribers.

Blue Apron shares had rebounded since last quarter’s report, and recently jumped on takeover rumors. But today’s news caused the stock to fall to less than a fifth of the IPO price, nearing all-time lows.

The stock market is in its 3rd-longest stretch without a new high since 2013

How long has the market been in the doldrums since scoring its most recent record? The S&P 500 index has gone about 48 trading daysnot including Fridaywithout notching a new high.

That lack of fresh highs is notable, not just because the S&P 500
SPX, -2.19%
and the Dow Jones Industrial Average
DJIA, -2.34%
are coming off an uncanny period of dormant volatility
VIX, +13.46%
and repeated all-time highs, but also because this fallow period for stocks is the third longest such span since 2013, according to Bespoke Investment Group in a Thursday note. The research and data group note that it is already the longest in about 5 years (see chart below).

The Dow and S&P 500 entered a correction phase back on Feb. 8, defined as a drop of at least 10% from a most recent peak set on Jan. 26.

Read: Why the worst may be over in the stock-market correction

If the S&P 500 goes another month, or about 20 trading days, without notching a fresh high it would surpass the period between the U.K.s market-roiling referendum to exit from out of the European Union and President Donald Trumps election, which appeared to unleashWall Streets animal spirits.

According to a report by MarketWatchs Ryan Vlastelica, since 1950, the average correction lasted for 61 trading days. That data dont include corrections that expand into a bear market, or a 20% drop from a peak.

However, Bespokes researchers are slightly more sanguine about what this current drawdown, another word for a decline in stock-market parlanceportends.

The Dow is around 9.2% lower from its late-Janua

Ameriprise Financial, Inc. (AMP) Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL reduced its stake in shares of Ameriprise Financial, Inc. (NYSE:AMP) by 3.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,574 shares of the financial services provider’s stock after selling 876 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Ameriprise Financial were worth $3,340,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. AXA grew its holdings in Ameriprise Financial by 26.3% during the 4th quarter. AXA now owns 497,212 shares of the financial services provider’s stock valued at $84,262,000 after buying an additional 103,465 shares in the last quarter. Crewe Advisors LLC purchased a new stake in Ameriprise Financial during the 4th quarter valued at approximately $133,000. Lazard Asset Management LLC grew its holdings in Ameriprise Financial by 5.7% during the 4th quarter. Lazard Asset Management LLC now owns 312,763 shares of the financial services provider’s stock valued at $53,003,000 after buying an additional 16,895 shares in the last quarter. BB&T Securities LLC grew its holdings in Ameriprise Financial by 1.1% during the 4th quarter. BB&T Securities LLC now owns 49,751 shares of the financial services provider’s stock valued at $8,431,000 after buying an additional 534 shares in the last quarter. Finally, Advisory Services Network LLC grew its holdings in Ameriprise Financial by 6.7% during the 4th quarter. Advisory Services Network LLC now owns 5,294 shares of the financial services provider’s stock valued at $897,000 after buying an additional 331 shares in the last quarter. 82.93% of the stock is owned by institutional investors and hedge funds.

Get Ameriprise Financial alerts:

A number of equities research analysts have issued reports on the stock. Credit Suisse Group assumed coverage on shares of Ameriprise Financial in a report on Wednesday, April 25th. They set a “neutral” rating and a $154.00 price objective for the company. Sandler O’Neill set a $158.00 target price on Ameriprise Financial and gave the company a “hold” rating in a research report on Tuesday, April 24th. Royal Bank of Canada set a $158.00 target price on Ameriprise Financial and gave the company a “hold” rating in a research report on Tuesday, April 24th. SunTrust Banks lowered their target price on Ameriprise Financial to $150.00 and set a “hold” rating for the company in a research report on Wednesday, April 25th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded Ameriprise Financial from a “hold” rating to a “buy” rating and set a $176.00 target price for the company in a research report on Thursday, March 22nd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $167.22.

In related news, VP Walter Stanley Berman purchased 3,728 shares of the stock in a transaction that occurred on Wednesday, May 2nd. The stock was bought at an average cost of $134.12 per share, for a total transaction of $499,999.36. Following the completion of the transaction, the vice president now directly owns 25,076 shares in the company, valued at $3,363,193.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO James M. Cracchiolo purchased 7,400 shares of the stock in a transaction that occurred on Thursday, May 10th. The stock was bought at an average price of $136.04 per share, with a total value of $1,006,696.00. Following the completion of the transaction, the chief executive officer now owns 242,416 shares of the company’s stock, valued at $32,978,272.64. The disclosure for this purchase can be found here. 1.50% of the stock is owned by company insiders.

NYSE AMP opened at $142.23 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.67 and a debt-to-equity ratio of 0.87. The company has a market cap of $20.57 billion, a PE ratio of 11.59 and a beta of 1.86. Ameriprise Financial, Inc. has a one year low of $118.84 and a one year high of $183.90.

Ameriprise Financial (NYSE:AMP) last posted its earnings results on Monday, April 23rd. The financial services provider reported $3.70 EPS for the quarter, beating analysts’ consensus estimates of $3.46 by $0.24. The firm had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.09 billion. Ameriprise Financial had a return on equity of 33.67% and a net margin of 13.59%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.52 EPS. sell-side analysts expect that Ameriprise Financial, Inc. will post 14.44 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, May 18th. Investors of record on Monday, May 7th were given a $0.90 dividend. The ex-dividend date of this dividend was Friday, May 4th. This is an increase from Ameriprise Financial’s previous quarterly dividend of $0.83. This represents a $3.60 dividend on an annualized basis and a yield of 2.53%. Ameriprise Financial’s dividend payout ratio (DPR) is currently 29.34%.

Ameriprise Financial Company Profile

Ameriprise Financial, Inc, through its subsidiaries, provides various financial products and services to individual and institutional clients in the United States and internationally. It operates through Advice & Wealth Management, Asset Management, Annuities, and Protection segments. The Advice & Wealth Management segment provides financial planning and advice, as well as full-service brokerage services primarily to retail clients through its advisors.

Want to see what other hedge funds are holding AMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ameriprise Financial, Inc. (NYSE:AMP).

Institutional Ownership by Quarter for Ameriprise Financial (NYSE:AMP)

Hot Low Price Stocks To Invest In 2019

What happened

Shares of Rogers Corp. (NYSE:ROG) gained 19.9% in April 2017, according to data from S&P Global Market Intelligence.

So what

The company reported first-quarter results on April 26, sending share prices nearly 12% higher the next day. Rogers saw 27% year-over-year sales growth and 79% higher earnings, leaving analyst estimates far behind in both cases.

A Rogers engineer, hard at work on next-generation battery materials. Image source: Rogers.

Now what

Rogers shares have now gained 72% over the last 52 weeks, trading steadily near all-time highs. The maker of specialized materials used in battery systems and wireless antennas has consistently delivered solid earnings surprises over the last three years, often coupled with equally strong revenue wins.

This company is poised to continue making a killing in several emerging markets, including the Internet of Things and automotive computing. Best of all, Rogers is winning competitive contracts without resorting to pricing discounts. Trailing operating margins have increased from 12.4% to 14.2% over the last four quarters. In other words, clients are choosing Rogers over rival materials providers for other reasons than low prices, such as product quality and dependable ordering and delivery processes.

Hot Low Price Stocks To Invest In 2019: Starwood Hotels & Resorts Worldwide, Inc.(HOT)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Hydro Protocol (CURRENCY:HOT) traded up 15.6% against the US dollar during the 24-hour period ending at 19:00 PM ET on May 5th. During the last week, Hydro Protocol has traded up 93.2% against the US dollar. One Hydro Protocol token can currently be purchased for approximately $0.10 or 0.00001044 BTC on major exchanges including BigONE, DDEX and OKEx. Hydro Protocol has a total market cap of $72.13 million and approximately $1.91 million worth of Hydro Protocol was traded on exchanges in the last day.

  • [By Ethan Ryder]

    Independent Research set a €156.00 ($185.71) price objective on Hochtief (FRA:HOT) in a research note issued to investors on Friday morning. The brokerage currently has a neutral rating on the stock.

  • [By Ethan Ryder]

    Holo (CURRENCY:HOT) traded down 9.1% against the US dollar during the 24 hour period ending at 8:00 AM Eastern on June 11th. Holo has a total market cap of $109.14 million and $2.40 million worth of Holo was traded on exchanges in the last day. One Holo token can now be purchased for about $0.0008 or 0.00000012 BTC on popular cryptocurrency exchanges including IDEX, Radar Relay, Hotbit and Fatbtc. During the last seven days, Holo has traded down 17.3% against the US dollar.

Hot Low Price Stocks To Invest In 2019: SEACOR Holdings, Inc.(CKH)

Advisors’ Opinion:

  • [By Stephan Byrd]

    State of Tennessee Treasury Department reduced its stake in shares of Seacor Holdings, Inc. (NYSE:CKH) by 9.5% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 11,943 shares of the oil and gas company’s stock after selling 1,254 shares during the period. State of Tennessee Treasury Department owned approximately 0.07% of Seacor worth $610,000 at the end of the most recent quarter.

  • [By Joseph Griffin]

    Headlines about Seacor (NYSE:CKH) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Seacor earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the oil and gas company an impact score of 45.3315874804175 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Hot Low Price Stocks To Invest In 2019: Full House Resorts, Inc.(FLL)

Advisors’ Opinion:

  • [By Logan Wallace]

    Huazhu Group (NASDAQ: HTHT) and Full House Resorts (NASDAQ:FLL) are both consumer discretionary companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Hot Low Price Stocks To Invest In 2019: Nabriva Therapeutics AG(NBRV)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Nabriva Therapeutics PLC – (NASDAQ:NBRV) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $4.20 and last traded at $4.39, with a volume of 8914 shares. The stock had previously closed at $4.29.

  • [By Lisa Levin]

    Shares of Nabriva Therapeutics plc (NASDAQ: NBRV) were down 14 percent to $4.6666 despite positive topline results from Phase 3 Lefamulin trial.

    Carver Bancorp, Inc. (NASDAQ: CARV) was down, falling around 21 percent to $6.59 after surging 201.37 percent on Thursday.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday.
    Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday.
    Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday.
    Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday.
    Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral.
    Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018.
    Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading.
    Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading

  • [By Ethan Ryder]

    Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.23. Nabriva Therapeutics had a negative return on equity of 79.30% and a negative net margin of 600.34%. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $1.27 million. equities analysts anticipate that Nabriva Therapeutics will post -1.9 EPS for the current fiscal year.

Hot Low Price Stocks To Invest In 2019: Schwab US Large-Cap ETF (SCHX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Milestone Group Inc. decreased its stake in Schwab US Large-Cap ETF (NYSEARCA:SCHX) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 63,425 shares of the company’s stock after selling 2,710 shares during the period. Schwab US Large-Cap ETF makes up 0.7% of Milestone Group Inc.’s investment portfolio, making the stock its 19th largest holding. Milestone Group Inc.’s holdings in Schwab US Large-Cap ETF were worth $4,001,000 as of its most recent filing with the Securities & Exchange Commission.

Best Bank Stocks To Invest In 2019

Earnings season is now in full session after JP Morgan (JPM ) and Citigroup (C ) beat earnings on Friday while Wells Fargo (WFC ) stumbled. Bank of America (BAC ) and Blackstone (BLK ) were the headliners on Monday, both surpassing expectations and boosting investor confidence.

BAC stock gained over 2.4% in morning trading Monday after reporting earnings of $0.63 on revenues of $22.6 billion. These surpassed our Zacks Consensus Estimates of $0.57 and $22.5 billion respectively. EPS numbers represented 43% year-over-year growth while revenue numbers slipped 1% from the year-ago quarter.

BLK’s adjusted earnings per share of $6.66 outpaced our estimate by six cents. Revenue numbers were equally solid, coming in at $3.61 billion and beating by $160 million. These figures grew 28% and 11% over the same period a year ago.

Moving forward, investor eyes will turn to Goldman Sachs (GS ) and Morgan Stanley (MS ) , which are slated to report earnings Tuesday and Wednesday before market open. Will they build on the momentum or bring recession worries back into the spotlight? Let’s take a look.

Best Bank Stocks To Invest In 2019: SPDR S&P 500 ETF (SPY)

Advisors’ Opinion:

  • [By Logan Wallace]

    Retirement Planning Group reduced its stake in SPDR S&P 500 Trust ETF (NYSEARCA:SPY) by 5.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,451 shares of the company’s stock after selling 264 shares during the quarter. SPDR S&P 500 Trust ETF makes up approximately 0.3% of Retirement Planning Group’s investment portfolio, making the stock its 20th biggest position. Retirement Planning Group’s holdings in SPDR S&P 500 Trust ETF were worth $1,171,000 as of its most recent filing with the SEC.

  • [By Max Byerly]

    Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in shares of SPDR S&P 500 Trust ETF (NYSEARCA:SPY) by 78.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,700 shares of the company’s stock after selling 6,169 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in SPDR S&P 500 Trust ETF were worth $447,000 at the end of the most recent quarter.

  • [By Selena Maranjian]

    You can also opt for exchange-traded funds, or ETFs, that focus on the same indexes — such as the SPDR S&P 500 ETF(NYSEMKT: SPY), Vanguard Total Stock Market ETF (NYSEMKT: VTI), and Vanguard Total World Stock ETF (NYSEMKT: VT). You can balance out your portfolio with bonds via index mutual funds and ETFs, too. The Vanguard Total Bond Market ETF (NYSEMKT: BND) is one such option.

Best Bank Stocks To Invest In 2019: Varex Imaging Corporation (VREX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Fluor Corporation (NYSE: FLR) fell 13.4 percent to $51.10 in pre-market trading after the company reported downbeat earnings for its first quarter and lowered its profit outlook for the year.
    Integrated Media Technology Limited (NASDAQ: IMTE) fell 9.8 percent to $28.97 in pre-market trading after surging 46.29 percent on Thursday.
    Gogo Inc. (NASDAQ: GOGO) shares fell 8.2 percent to $8.81 in pre-market trading after the company reported Q1 results and disclosed that it is withdrawing its FY18 outlook for adjusted EBITDA, airborne cash capex, airborne equipment inventory purchases and free cash flow.
    Sharing Economy International Inc. (NASDAQ: SEII) shares fell 7.5 percent to $3.98 in pre-market trading after climbing 22.16 percent on Thursday.
    Arista Networks, Inc. (NYSE: ANET) fell 7.4 percent to $248.00 in pre-market trading following first-quarter earnings.
    Web.com Group, Inc. (NASDAQ: WEB) fell 6.7 percent to $18.00 in pre-market trading after reporting Q1 results.
    Varex Imaging Corporation (NASDAQ: VREX) fell 5.2 percent to $34 in pre-market trading after reporting Q2 results.
    Turkcell Iletisim Hizmetleri A.S. (NYSE: TKC) shares fell 5.2 percent to $7.60 in pre-market trading after dropping 3.02 percent on Thursday.
    AMN Healthcare Services, Inc (NYSE: AMN) shares fell 4.7 percent to $61.70 in pre-market trading following Q1 earnings.
    HSBC Holdings plc (NYSE: HSEA) fell 4.6 percent to $25.15 in pre-market trading after reporting Q1 results.
    Stratasys Ltd. (NASDAQ: SSYS) shares fell 4 percent to $16.66 in pre-market trading after dropping 2.86 percent on Thursday.
    Melco Resorts & Entertainment Limited (NASDAQ: MLCO) fell 4 percent to $30.65 in pre-market trading.
    Century Aluminum Co (NASDAQ: CENX) fell 4 percent to $15.76 in pre-market trading following Q1 results.
    HSBC Holdings plc (NYSE: HSBC) shares fell 3.5 percent to $48.10 in pre-market tr

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Varex Imaging (VREX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Orelli]

    Shares of Varex Imaging (NASDAQ:VREX) are plunging today, down 27% as of 1:27 p.m. EDT, after the company announced disappointing results for its fiscal third quarter following the closing bell yesterday. Investors are fretting about how a trade war will affect the X-ray component maker’s growth prospects.

  • [By Logan Wallace]

    Prudential Financial Inc. lifted its holdings in Varex Imaging Corp (NASDAQ:VREX) by 2.7% during the 1st quarter, HoldingsChannel reports. The fund owned 63,814 shares of the company’s stock after acquiring an additional 1,700 shares during the quarter. Prudential Financial Inc.’s holdings in Varex Imaging were worth $2,283,000 at the end of the most recent reporting period.

Best Bank Stocks To Invest In 2019: Teladoc, Inc.(TDOC)

Advisors’ Opinion:

  • [By Max Byerly]

    Teladoc Inc (NYSE:TDOC) CEO Jason N. Gorevic sold 25,000 shares of the stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $60.21, for a total value of $1,505,250.00. Following the completion of the transaction, the chief executive officer now owns 611,184 shares of the company’s stock, valued at $36,799,388.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

  • [By Simon Erickson]

    Teladoc’s (NYSE:TDOC) first-quarter results kicked off a good start to 2018. Their now fully integrated acquisition of Best Doctors helped revenue more than double for the second straight quarter and U.S. membership reach more than 20 million people.

  • [By Motley Fool Staff]

    In this segment fromIndustry Focus: Healthcare, host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to discuss how innovative companies like Teladoc (NYSE:TDOC) are transforming how patients receive healthcare.

  • [By Demitrios Kalogeropoulos, Jeremy Bowman, and Steve Symington]

    Investors looking for steadier returns might consider buying stocks instead. And the good news is, at least in the case ofiRobot (NASDAQ:IRBT), Twilio (NYSE:TWLO), and Teledoc (NYSE:TDOC), you can still expose yourself to disruptive technologies while benefiting from the more predictable growth that stocks provide.

  • [By Shane Hupp]

    Teladoc (NYSE:TDOC) CEO Jason N. Gorevic sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $48.93, for a total transaction of $1,223,250.00. Following the transaction, the chief executive officer now directly owns 636,184 shares in the company, valued at approximately $31,128,483.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

$0.09 Earnings Per Share Expected for WisdomTree Investments (WETF) This Quarter

Equities analysts predict that WisdomTree Investments (NASDAQ:WETF) will post earnings of $0.09 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for WisdomTree Investments’ earnings. The highest EPS estimate is $0.11 and the lowest is $0.08. WisdomTree Investments also posted earnings per share of $0.09 during the same quarter last year. The business is scheduled to report its next earnings report on Friday, July 27th.

On average, analysts expect that WisdomTree Investments will report full year earnings of $0.38 per share for the current year, with EPS estimates ranging from $0.35 to $0.41. For the next year, analysts expect that the business will report earnings of $0.47 per share, with EPS estimates ranging from $0.44 to $0.52. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for WisdomTree Investments.

Get WisdomTree Investments alerts:

WisdomTree Investments (NASDAQ:WETF) last issued its quarterly earnings data on Friday, April 27th. The asset manager reported $0.08 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.08. The firm had revenue of $59.61 million during the quarter, compared to the consensus estimate of $59.32 million. WisdomTree Investments had a return on equity of 18.28% and a net margin of 12.27%. The firm’s revenue was up 9.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.05 EPS.

A number of research analysts recently commented on the company. Keefe, Bruyette & Woods restated a “hold” rating and set a $12.00 price objective on shares of WisdomTree Investments in a research note on Friday, February 2nd. Deutsche Bank lowered their price objective on WisdomTree Investments from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, April 6th. Citigroup lowered their price objective on WisdomTree Investments from $15.00 to $13.50 and set a “buy” rating for the company in a research note on Tuesday, February 6th. Bank of America lowered their price objective on WisdomTree Investments from $10.00 to $9.50 and set an “underperform” rating for the company in a research note on Monday, February 5th. Finally, Zacks Investment Research cut WisdomTree Investments from a “hold” rating to a “sell” rating in a research note on Saturday, April 14th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $11.98.

WETF traded up $0.17 during trading on Friday, reaching $11.67. 140,750 shares of the company were exchanged, compared to its average volume of 1,574,151. The company has a market cap of $1.74 billion, a P/E ratio of 48.48, a PEG ratio of 2.00 and a beta of 2.63. WisdomTree Investments has a 52 week low of $11.55 and a 52 week high of $11.72.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 23rd. Stockholders of record on Wednesday, May 9th will be paid a $0.03 dividend. The ex-dividend date of this dividend is Tuesday, May 8th. This represents a $0.12 annualized dividend and a dividend yield of 1.03%. WisdomTree Investments’s payout ratio is 50.00%.

In other news, insider David J. Abner sold 25,000 shares of the company’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $10.52, for a total value of $263,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael H. Steinhardt sold 177,009 shares of the company’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $9.94, for a total value of $1,759,469.46. The disclosure for this sale can be found here. In the last three months, insiders sold 941,936 shares of company stock valued at $9,354,156. Company insiders own 16.60% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. TimesSquare Capital Management LLC lifted its holdings in shares of WisdomTree Investments by 16.3% in the fourth quarter. TimesSquare Capital Management LLC now owns 8,403,900 shares of the asset manager’s stock valued at $105,469,000 after buying an additional 1,176,600 shares during the period. Fred Alger Management Inc. lifted its holdings in shares of WisdomTree Investments by 26.2% in the fourth quarter. Fred Alger Management Inc. now owns 7,392,054 shares of the asset manager’s stock valued at $92,770,000 after buying an additional 1,535,994 shares during the period. Clearbridge Investments LLC lifted its holdings in shares of WisdomTree Investments by 0.7% in the fourth quarter. Clearbridge Investments LLC now owns 4,842,415 shares of the asset manager’s stock valued at $60,772,000 after buying an additional 34,160 shares during the period. Standard Life Aberdeen plc lifted its holdings in shares of WisdomTree Investments by 19.4% in the fourth quarter. Standard Life Aberdeen plc now owns 3,694,333 shares of the asset manager’s stock valued at $46,383,000 after buying an additional 600,276 shares during the period. Finally, Granite Investment Partners LLC lifted its holdings in shares of WisdomTree Investments by 1.7% in the fourth quarter. Granite Investment Partners LLC now owns 1,483,974 shares of the asset manager’s stock valued at $18,624,000 after buying an additional 24,513 shares during the period. Institutional investors and hedge funds own 77.00% of the company’s stock.

WisdomTree Investments Company Profile

WisdomTree Investments, Inc, through its subsidiaries, operates as an exchange-traded funds (ETFs) sponsor and asset manager. It offers ETFs in equities, currency, fixed income, and alternatives asset classes. The company also licenses its indexes to third parties for proprietary products, as well as offers a platform to promote the use of WisdomTree ETFs in 401(k) plans.

Get a free copy of the Zacks research report on WisdomTree Investments (WETF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for WisdomTree Investments (NASDAQ:WETF)

U.S. stock futures buoyed by Apple euphoria, but trade flat ahead of jobs report

U.S. major stock-index benchmarks saw muted trade Friday, a day after investors scored a boost from the technology and internet-related sector after Apple Inc. became the first U.S. public company to surpass a market capitalization of $1 trillion. However, all eyes are on the jobs report, which is due early in the session and should help influence the buying mood on Wall Street.

What are benchmarks doing?

Futures for the Dow Jones Industrial Average
YMU8, +0.09%
were up 9 points, or less than 0.1%, at 25,315, while those for the S&P 500 index
ESU8, +0.08%
put on 1.10 points, or less than 0.1%, at 2,829.50. Meanwhile, futures for the tech-laden Nasdaq-100 index
NQU8, +0.10%
added 5.75 points, or 0.1%, at 7,391.50.

On Thursday, The S&P 500
SPX, +0.49%
rose 13.86 points to 2,827.22, for a gain of 0.5%. The Nasdaq Composite Index
COMP, +1.24%
closed 95.40 points, or 1.2%, higher to 7,802.69, on the back of Apple Inc.s share
AAPL, +2.92%
advance, but the Dow
DJIA, -0.03%
struggled to hold onto gains, and closed off 7.66 points, or less than 0.1%, to 25,326.16, as that gauge wobbled on trade jitters.

Whats driving markets?

Wall Street has been caught up in a battle of concern over the U.S.s trade spats with developed economies such as China versus optimism over economic and quarterly earnings results that have been outstanding by most measures.

Fridays nonfarm-payrolls report for July could be the impetus that determines the next phase for U.S. equity benchmarks, which remain a few percentage points from all-time highs. The focus in Fridays report will be whether wages are picking up, a harbinger of higher inflation. That could in turn influence the Federal Reserves monetary policy plan, which was held in check at its latest meeting on Wednesday. The Feds policy update affirmed the central banks intention to lift interest rates at least once more before the end of 2018.

Economists polled by MarketWatch predict an increase of 194,000 new jobs for July, with the unemployment rate set to tick down to 3.9% and average hourly wages slated to show a rise of 0.2%.

The report is due to be released at 8:30 a.m. Eastern Daylight Savings Time.

Check out: U.S. jobs report for July likely to be another good one, but the real story is rising wages

What else is on investors radar?

Beyond the jobs report, investors will await a report on the trade deficit for June, with a deficit of $46 billion expected. At 9:45 a.m. Eastern, a Markit services report for July is scheduled, with the ISM nonmanufacturing index for the same month due for release at 10 a.m.

Elsewhere, investors are watching signs of economic slowdown in China. A private gauge showed service sector activity in the country continued to grow in July, but at a slower pace than in June. Chinas economy, already facing a slide, has been hurt by the tariff clash with the U.S.

Key Chinese equity index the Shanghai Composite
SHCOMP, -1.00%
fell 1%, while the Shenzhen Composite
399106, -1.72%
declined by 1.7% after hitting a 3陆-year closing low in the prior session.

Which stocks are in focus?

Dish Network Corp.
DISH, -2.07%
soared in premarket trade Friday, after the satellite pay-TV service reported better-than-expected second-quarter earnings and revenue.

Shares of CBS Corp.
CBS, +0.32%
will be in focus after the media company late-Thursday reported second-quarter earnings that came in below expectations but narrowly topped revenue forecasts for the quarter. CBS on Wednesday said its board of directors had hired outside lawyers to conduct an investigation into allegations that Chief Executive Les Moonves had sexually harassed women. Thursdays earnings statement made no mention of Moonves status.

Apple
AAPL, +2.92%
made history on Thursday become the first U.S. company on Thursday to reach a valuation of $1 trillion, following its better-than-expected quarterly results.

Providing critical information for the U.S. trading day. Subscribe to MarketWatch's free Need to Know newsletter. Sign up here.

Mark DeCambre

Mark DeCambre is MarketWatch’s markets editor. He is based in New York. Follow him on Twitter @mdecambre.

We Want to Hear from You

Join the conversation

Comment

Related Topics U.S. Stocks Markets NY Stock Exchange NASDAQ

Quote References YMU8 +24.00 +0.09% ESU8 +2.25 +0.08% NQU8 +7.25 +0.10% SPX +13.86 +0.49% COMP +95.40 +1.24% AAPL +5.89 +2.92% DJIA -7.66 -0.03% SHCOMP -27.58 -1.00% 399106 -25.99 -1.72% DISH -0.63 -2.07% CBS +0.17 +0.32% Show all references
MarketWatch Partner Center
Most Popular Amid Twitter beef, Foxs Sean Hannity says hed be the first person to jump in and fight to defend CNNs Jim Acosta Tesla short sellers are sitting on a paper loss of nearly $2 billion after stock rally Seven reasons why you need to lighten up on stocks today Amazons Jeff Bezos would need to spend $28 million a day to avoid getting richer What to Wear to a Star Wars Wedding

Community Guidelines FAQs

BACK TO TOP MarketWatch Site Index Topics Help Feedback Newsroom Roster Media Archive